ArticleThe World Allergy Organization journal2025
A sensitive and specific assay to characterize plasma kallikrein activity in plasma from patients with hereditary angioedema.
Article in The World Allergy Organization journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic Targeting of the Bradykinin B2 Receptor in Immunological and Vascular Diseases: Insights from Kinin Biology to Clinical Outcomes.Clinical reviews in allergy & immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Plasma kallikrein (PKa) activity is increased in the plasma of patients with hereditary angioedema (HAE) and has been implicated in other kallikrein-kinin system (KKS)-mediated diseases. Exogenous substrates commonly used in PKa assays can be cleaved by multiple plasma proteases, which reduce assay specificity and sensitivity for PKa. We describe a sensitive and specific assay to detect PKa activity in plasma as a candidate biomarker for HAE. Methods: PKa activity was measured in plasma samples from patients with HAE with decreased C1 inhibitor (C1INH) levels or activity who were not receiving prophylactic medications for HAE (HAE-C1INH; Results: In control plasma, sPKa activity was 0.69 ± 0.07 nmol/min/mL at baseline and 0.88 ± 0.11 nmol/min/mL after 6 h of cold incubation (mean ± SEM, Conclusion: We developed a specific PKa assay that can detect low levels of PKa activity in plasma and can differentiate patients with HAE-C1INH from controls without HAE with high sensitivity and specificity. Using this assay, we demonstrated that sPKa activity is elevated during the intercritical period in patients with HAE-C1INH and in those with HAE-nC1INH compared with controls when measured after 6 h of cold incubation. This sensitive and specific PKa assay could be useful to characterize PKa activity in plasma samples from patients with HAE and could potentially serve as a future candidate biomarker for HAE-nC1INH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.